Gomase Virendra S, Sharma Rupali, Sardana Satish
Prin. L. N. Welingkar Institute of Management Development & Research, Mumbai, 400019, India.
Amity Institute of Pharmacy (AIP), Amity University, Amity Education Valley, Pachgaon, Manesar, Gurgaon, 122413, Haryana, India.
Rev Recent Clin Trials. 2025 Aug 18. doi: 10.2174/0115748871366461250802092217.
The pharmaceutical industry operates within a complex regulatory environment, requiring strict compliance with global guidelines. Regulatory affairs (RA) departments are pivotal in ensuring drug approvals and compliance. However, the increasing complexity and volume of regulatory requirements have put a strain on traditional processes, driving the adoption of automation tools to streamline these operations.
This review aims to explore the key automation tools used in regulatory affairs, focusing on their role in streamlining submissions, ensuring compliance, centralizing data, and reducing human error. It also aims to examine the emerging technologies in the field and their potential for enhancing automation.
A comprehensive review of current automation tools in regulatory affairs was conducted. The key tools explored include Submission Management Systems (SMS), Regulatory Information Management (RIM) systems, Electronic Document Management Systems (EDMS), and Regulatory Intelligence Tools. Additionally, the role of emerging technologies like Artificial Intelligence (AI) and Machine Learning (ML) in automating regulatory processes was evaluated.
Automation tools such as SMS, RIM, EDMS, and Regulatory Intelligence Tools have been found to significantly improve the efficiency of regulatory affairs operations. These tools streamline submissions, centralize data, and ensure compliance. AI and ML technologies further enhance automation by enabling predictive analytics and automating risk assessments. Despite the advantages, challenges remain, including high implementation costs, data security concerns, and the need to adapt to varying global regulations. However, overcoming the challenges and limitations associated with these technologies in adopting regulatory automation is crucial.
This study highlights that automation tools are important for modernizing regulatory affairs by improving efficiency, accuracy, and compliance. The integration of Artificial Intelligence (AI) and Machine Learning (ML) adds predictive and adaptive capabilities, transforming static processes into dynamic systems. These technologies hold immense potential to reshape regulatory operations globally.
Automation tools are becoming essential in the pharmaceutical industry to maintain regulatory compliance, reduce time-to-market, and manage the increasing complexity of drug development in a globalized industry. As emerging technologies like AI, ML, and blockchain continue to evolve, they promise to further revolutionize regulatory affairs processes.
制药行业在复杂的监管环境中运作，需要严格遵守全球准则。监管事务（RA）部门在确保药物获批和合规方面起着关键作用。然而，监管要求的日益复杂和数量不断增加给传统流程带来了压力，促使采用自动化工具来简化这些操作。
本综述旨在探讨监管事务中使用的关键自动化工具，重点关注它们在简化申报、确保合规、集中数据和减少人为错误方面的作用。它还旨在研究该领域的新兴技术及其增强自动化的潜力。
对监管事务中当前的自动化工具进行了全面综述。所探讨的关键工具包括申报管理系统（SMS）、监管信息管理（RIM）系统、电子文档管理系统（EDMS）和监管情报工具。此外，还评估了人工智能（AI）和机器学习（ML）等新兴技术在自动化监管流程中的作用。
已发现诸如SMS、RIM、EDMS和监管情报工具等自动化工具能显著提高监管事务操作的效率。这些工具简化申报、集中数据并确保合规。AI和ML技术通过实现预测分析和自动化风险评估进一步增强了自动化。尽管有这些优势，但挑战依然存在，包括高实施成本、数据安全问题以及需要适应不同的全球法规。然而，在采用监管自动化时克服与这些技术相关的挑战和限制至关重要。
本研究强调，自动化工具对于通过提高效率、准确性和合规性来实现监管事务现代化很重要。人工智能（AI）和机器学习（ML）的整合增加了预测和自适应能力，将静态流程转变为动态系统。这些技术在全球范围内重塑监管操作方面具有巨大潜力。
自动化工具在制药行业中变得至关重要，可以维持监管合规、缩短上市时间并管理全球化行业中药物开发日益增加的复杂性。随着AI、ML和区块链等新兴技术不断发展，它们有望进一步彻底改变监管事务流程。
